深 沪
undefined undefined
--
NaN.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 振 幅 NaN.00%
- 最 低 --
- 昨 收 --
- 成交额 --
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioAge Labs full-year collaboration revenue beats estimates
BioAge Labs full-year collaboration revenue beats estimates Overview US biopharmaceutical firm posts full-year collaboration revenue, beating analyst expectations Net loss for 2025 widened as R&D and G&A expenses increased Company completed $132.3 mln upsized follow-on public offering to fund operat
03-24 21:09
BRIEF-ADES Holding Says Some GCC Offshore Rigs Recently Suspended Amid Regional Tensions
BRIEF-ADES Holding Says Some GCC Offshore Rigs Recently Suspended Amid Regional Tensions March 24 (Reuters) - ADES Holding Company Listed JSC 2382.SE : ADES HOLDING - ANNOUNCES FY2026 EBITDA GUIDANCE IMPLYING 33-44% INCREASE FROM PRIOR YEAR'S UPPER-END GUIDANCE ADES HOLDING - A HANDFUL OF GROUP’S OF
03-24 13:39
ROI-Why $100 oil won't break the American consumer: McGeever
ROI-Why $100 oil won't break the American consumer: McGeever The opinions expressed here are those of the author , a columnist for Reuters. By Jamie McGeever ORLANDO, Florida, March 23 (Reuters) - No one likes expensive oil, especially in the U.S., where driving, spending, and energy-intensive econo
03-23 21:00
Talphera Q4 net loss widens as operating expenses rise
Talphera Q4 net loss widens as operating expenses rise Overview US specialty pharma firm's Q4 net loss widened yr/yr, with negligible revenue Operating expenses rose, driven by Niyad development and increased G&A costs Company closed $4.1 mln financing tranche after reaching 50% enrollment in NEPHRO
03-23 20:39
Avalo Therapeutics posts lower-than-expected 2025 net loss
Avalo Therapeutics posts lower-than-expected 2025 net loss Overview U.S. IL-1β drug developer's 2025 net loss is lower than expected Operating expenses rose due to increased R&D for Phase 2 LOTUS trial Outlook Company expects cash and investments at Dec 31, 2025, to fund operations into 2028 Result
03-23 19:12
Pyxis Oncology 2025 net loss widens on higher R&D spend
Pyxis Oncology 2025 net loss widens on higher R&D spend Overview US biopharmaceutical developer's 2025 revenue fell yr/yr, net loss widened Company completed target enrollment in MICVO Phase 1 monotherapy study for head and neck cancer Pyxis Oncology expects cash runway into fourth quarter of 2026 O
03-23 19:09
WRAPUP 1-Unexpected decline in US weekly jobless claims signals stable labor market
WRAPUP 1-Unexpected decline in US weekly jobless claims signals stable labor market Weekly jobless claims decrease 8,000 to 205,000 Continuing claims increase 10,000 to 1.857 million By Lucia Mutikani WASHINGTON, March 19 (Reuters) - The number of Americans filing new applications for unemployment b
03-19 22:13
BRIEF-MFS Owner Paresh Raja Hit With Worldwide Freezing Order - FT
BRIEF-MFS Owner Paresh Raja Hit With Worldwide Freezing Order - FT March 18 (Reuters) - MFS OWNER PARESH RAJA HIT WITH WORLDWIDE FREEZING ORDER - FT MFS' RAJA MUST PROVIDE DETAILS OF ALL ASSETS WORTH MORE THAN £10,000; PREVENTED FROM SPENDING OVER £5,000 A WEEK WITHOUT CONSENT OF ADMINISTRATORS- FT
03-18 21:07
BRIEF-Aspen Group Reports Fourth Consecutive Quarter Of Net Income For Third Quarter Fiscal 2026
BRIEF-Aspen Group Reports Fourth Consecutive Quarter Of Net Income For Third Quarter Fiscal 2026 March 16 (Reuters) - Aspen Group Inc ASPU.PK : ASPEN GROUP REPORTS FOURTH CONSECUTIVE QUARTER OF NET INCOME FOR THIRD QUARTER FISCAL 2026 Source text: ID:nGNX5fkjJJ Further company coverage: ASPU.PK (( R
03-16 20:18
BRIEF-Aspen Group Announces Leadership Transition
BRIEF-Aspen Group Announces Leadership Transition March 16 (Reuters) - Aspen Group Inc ASPU.PK : ASPEN GROUP ANNOUNCES LEADERSHIP TRANSITION ASPEN GROUP INC - APPOINTS MATT LAVAY AS CEO AND BOARD MEMBER EFFECTIVE MARCH 16 Source text: ID:nGNX7wBdhG Further company coverage: ASPU.PK (( Reuters.Briefs
03-16 20:00
